(Q38203330)

30 August 2017

title

Potential new clinical therapies for Chagas disease (English)

1 reference

30 August 2017

0 references

Rick L Tarleton

2

0 references

author name string

Juan M Bustamante

series ordinal

1

1 reference

30 August 2017

language of work or name

English

0 references

publication date

9 April 2014

1 reference

Expert Review of Clinical Pharmacology

30 August 2017

published in

1 reference

30 August 2017

volume

7

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

317-325

1 reference

Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Trypanosoma cruzi and Chagas' Disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Chagas disease in Spain, the United States and other non-endemic countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Eliminating Chagas disease: challenges and a roadmap

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

A critical review on Chagas disease chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Advances in Chagas disease drug development: 2009-2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Molecular evolution of biomembranes: structural equivalents and phylogenetic precursors of sterols

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Aetiological treatment with itraconazole or ketoconazole in individuals with Trypanosoma cruzi/HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Pharmacological Characterization, Structural Studies, and In Vivo Activities of Anti-Chagas Disease Lead Compounds Derived from Tipifarnib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

VNI cures acute and chronic experimental Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Nonpeptidic Tetrafluorophenoxymethyl Ketone Cruzain Inhibitors as Promising New Leads for Chagas Disease Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Reversible cysteine protease inhibitors show promise for a Chagas disease cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Acidocalcisomes - conserved from bacteria to man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Therapeutic approaches to bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Risedronate in the treatment of Murine Chagas' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Antiparasitic activity of risedronate in a murine model of acute Chagas' disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Design, Synthesis, Calorimetry, and Crystallographic Analysis of 2-Alkylaminoethyl-1,1-bisphosphonates as Inhibitors of Trypanosoma cruzi Farnesyl Diphosphate Synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Design, synthesis and biological evaluation of sulfur-containing 1,1-bisphosphonic acids as antiparasitic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

2-alkylaminoethyl-1,1-bisphosphonic acids are potent inhibitors of the enzymatic activity of Trypanosoma cruzi squalene synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Metabolism and functions of trypanothione in the Kinetoplastida

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Thioridazine treatment prevents cardiopathy in Trypanosoma cruzi infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Thioridazine treatment modifies the evolution of Trypanosoma cruzi infection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Use of clomipramine as chemotherapy of the chronic phase of Chagas disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

The chemotherapy of chagas' disease: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Specific chemotherapy of Chagas disease: controversies and advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Association of clomipramine and allopurinol for the treatment of the experimental infection with Trypanosoma cruzi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Functional roles for amino acids in active site loop II of a hypoxanthine phosphoribosyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

The Trypanosoma cruzi proteome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Fexinidazole: a potential new drug candidate for Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Boron-based drugs as antiprotozoals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Therapeutic potential of boron-containing compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Combined treatment with benznidazole and allopurinol in mice infected with a virulent Trypanosoma cruzi isolate from Nicaragua.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Benznidazole shortage makes chagas disease a neglected tropical disease in developed countries: data from Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Towards a paradigm shift in the treatment of chronic Chagas disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Transgenic parasites accelerate drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Supply chain problems for Chagas disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

Bisphosphonate metal complexes as selective inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2014.909282

10.1586/17512433.2014.909282

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference